Results from a Joined Prospective Study to Evaluate the Sensitivity of the In Vivo Dog QT Assay in Line with the ICH E14/S7B Q&A Best Practices
- 6 May 2024
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (1) , 106-116
Abstract
The ICH E14/S7B Q&As highlighted the need for best practices concerning the design, execution, analysis, interpretation, and reporting of the in vivo non‐rodent QT assay as a component of the integrated risk assessment to potentially support a TQT waiver or substitute. We conducted a dog telemetry study to assess the effects on QTc of six reference compounds (five positive and one negative) previously evaluated by Darpo et al. (2015) in humans. The sensitivity of the assay to detect QTc increases was determined, and exposure–response analysis was performed, as done in clinical practice. By‐timepoint analysis showed QTc prolongation induced by moxifloxacin, dofetilide, dolasetron, ondansetron, and quinine within human relevant plasma exposures ranges. Moreover, a hysteresis was observed for quinine. As expected, levocetirizine showed no statistically significant effect on QTc across a range of exposure, well exceeding the therapeutic Cmax. Power analyses confirmed the study ability to detect statistically significant QTc changes of less than 10 milliseconds with 80% probability, even with a sample size as low as n = 4 animals. Finally, concentration‐QTc modeling enabled to predict the minimal plasma concentration needed to detect a 10 milliseconds QTc prolongation, including for quinine. The comparison with clinical available data supported the relevance of dogs under these experimental conditions as a robust translational predictor of drug‐induced QTc prolongation in humans as a key pillar of the integrated risk assessment.Keywords
This publication has 35 references indexed in Scilit:
- Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates)Clinical Pharmacology & Therapeutics, 2020
- Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry PerspectiveClinical Pharmacology & Therapeutics, 2020
- Cardiac sodium channel antagonism – Translation of preclinical in vitro assays to clinical QRS prolongationJournal of Pharmacological and Toxicological Methods, 2018
- Sensitivity of pharmacokinetic–pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testingJournal of Pharmacological and Toxicological Methods, 2015
- Results From the IQ‐CSRC Prospective Study Support Replacement of the Thorough QT Study by QT Assessment in the Early Clinical PhaseClinical Pharmacology & Therapeutics, 2014
- Preclinical QT safety assessment: Cross-species comparisons and human translation from an industry consortiumJournal of Pharmacological and Toxicological Methods, 2014
- Translational pharmacokinetic–pharmacodynamic modeling of QTc effects in dog and humanJournal of Pharmacological and Toxicological Methods, 2013
- Pharmacokinetic–pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeysJournal of Pharmacological and Toxicological Methods, 2011
- A novel approach to data processing of the QT interval response in the conscious telemetered beagle dogJournal of Pharmacological and Toxicological Methods, 2007
- Terfenadine-associated ventricular arrhythmias and QTc interval prolongationAnnals of Epidemiology, 1995